Compare Devon Energy Corp (DVN) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Devon Energy Corp vs Viatris Inc — how do they compare? Devon Energy Corp trades at $44.87 (market cap $49.94B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Devon Energy Corp is far larger — about 2.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| DVN | VTRS | |
|---|---|---|
Market Cap | $49.94B | $18.69B |
Sector | Energy | Health |
52-Week High | $52.07 | $17.86 |
52-Week Low | $31.74 | $9.49 |
Enterprise Value | $60.68B | $30.80B |
Dividend Yield | 2.82% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Devon Energy (DVN) trades at $44.9, down 1.01% today, with a bullish technical signal and strong Q2 2026 earnings beat. The company reported EPS of $1.57 versus $1.40 expected, driven by merger synergies and higher oil prices. Valuation remains attractive with a P/E of 9.87 and P/S of 1.62. Recent news highlights a 33% dividend increase and $1.25 billion debt repayment, reinforcing financial health.
The outlook is positive given robust free cash flow, debt reduction targets, and analyst consensus price target of $61.91 implying 38% upside. Key risks include oil price volatility and integration challenges from the Coterra merger. Institutional sentiment is strongly bullish with 71% buy ratings, supporting a favorable risk-reward profile for long-term investors.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
